Recent studies found frequent NRAS and KRAS mutations in the ELN favorable core-binding factors AML subtype, and showed that the presence of subclones carrying RAS gene mutations identified, among these seemingly good prognostic patients, those having a reduced survival probability [44]. This evidence concerns the gene NRAS and acute myeloid leukemia.